Hypertrophic Cardiomyopathy: Sequencing Panel

Create a PDF of this page

Condition Description

Hereditary hypertrophic cardiomyopathy (HCM) is inherited in an autosomal dominant manner. HCM is characterized by left ventricular hypertrophy in the absence of a predisposing cardiac or cardiovascular condition. The manifestation of HCM is extremely variable, even within the same family, and can range from asymptomatic to progressive heart failure. Other features include syncope, presyncope, shortness of breath, chest pain, orthostasis, and palpitations. The onset of HCM is usually during adolescence or young adulthood; however, it can range from infancy to much later in adult life. The prevalence of HCM is approximately 1 in 500 and ~55-70% of cases are caused by a mutation in one of the genes that encode a part of the sarcomere.            

Reference:
  • GeneReviews

Genes (20)

Evidence

Loading Data . . .
GeneOMIM TermContribution to DiseaseEvidence LevelPublications
ACTC1Cardiomyopathy, hypertrophic, 11MinorStrongHershberger RE (2009)Available tests
CAV3Cardiomyopathy, familial hypertrophicMinorStrongHayashi T (2003)Available tests
GLA Fabry disease; Fabry disease, cardiac variantMajorStrongHershberger RE (2009)Available tests
JPH2Cardiomyopathy, hypertrophic, 17MinorStrongLandstrom AP (2007)Available tests
LAMP2Danon diseaseMinorStrongHershberger RE (2009)Available tests
LAMP2Danon diseaseMinorStrongCheng Z (2012)Available tests
MYBPC3Cardiomyopathy, hypertrophic, 4MajorStrongHershberger RE (2009)Available tests
MYH6Cardiomyopathy, hypertrophic, 14MajorStrongHershberger RE (2009)Available tests
MYH7Cardiomyopathy, hypertrophic, 1MajorStrongHershberger RE (2009)Available tests
MYL2Cardiomyopathy, hypertrophic, 10MajorStrongHershberger RE (2009)Available tests
MYL3Cardiomyopathy, hypertrophic, 8MinorStrongHershberger RE (2009)Available tests
MYOZ2Cardiomyopathy, hypertrophic, 16MinorStrongOsio A (2007)Available tests
MYPN Cardiomyopathy, dilated, 1KK; Cardiomyopathy, familial restrictive, 4; Cardiomyopathy, hypertrophic, 22MinorStrongHershberger RE (2011)Available tests
MYPN Cardiomyopathy, dilated, 1KK; Cardiomyopathy, familial restrictive, 4; Cardiomyopathy, hypertrophic, 22MinorStrongPurevjav E (2012)Available tests
PRKAG2Cardiomyopathy, hypertrophic 6MinorStrongHershberger RE (2009)Available tests
TNNC1Cardiomyopathy, hypertrophic, 13MinorStrongLandstrom AP (2008)Available tests
TNNI3Cardiomyopathy, hypertrophic, 7MinorStrongHershberger RE (2009)Available tests
TNNT2Cardiomyopathy, hypertrophic, 2MajorStrongHershberger RE (2009)Available tests
TPM1Cardiomyopathy, hypertrophic, 3MinorStrongHershberger RE (2009)Available tests
TTNCardiomyopathy, familial hypertrophic, 9MinorStrongHerman DS (2012)Available tests
TTRAmyloidosis, hereditary, transthyretin-relatedMinorStrongMohty D (2013)Available tests

Indications

This test is indicated for individuals with:
  • Confirmation of a clinical diagnosis of hereditary hypertrophic cardiomyopathy (HCM).
  • Carrier testing in adults with a family history of hereditary hypertrophic cardiomyopathy (HCM).

Methodology

Next Generation Sequencing: In-solution hybridization of all coding exons is performed on the patient's genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not meant to interrogate most promoter regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplications. Direct sequencing of the captured regions is performed using next generation sequencing. The patient's gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.

Detection

Next Generation Sequencing: Clinical Sensitivity: Unknown. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions/duplications will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's clinical/biochemical phenotype.

Analytical Sensitivity: ~99%.

Specimen Requirements

Submit only 1 of the following specimen types

Type: Whole Blood

Specimen Requirements:

In EDTA (purple top) tube:
Infants (<2 years): 2-3 ml
Children (>2 years): 3-5 ml
Older Children & Adults: 5-10 ml.

Specimen Collection and Shipping: Ship sample at room temperature with overnight delivery.

Type: Isolated DNA

Specimen Requirements:

In microtainer: 60 ug

Isolation using the QiagenTM Puregene kit for DNA extraction is recommended.

Specimen Collection and Shipping: Refrigerate until time of shipment in 100 ng/ul of TE buffer. Ship sample at room temperature with overnight delivery.

  • Comprehensive Cardiomyopathy Sequencing Panel.
  • Hypertrophic Cardiomyopathy: Deletion/Duplication Panel.

How to Order